Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue remains negative
Q4 FY2025 cost of revenue was $0, compared with $58K a year earlier. Trailing-twelve-month cost of revenue was $120K. Over 3 fiscal years it compounded at -6.4% a year.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $30K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 100K USD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -4.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100K | -16.7% |
| FY2024 | 2024-12-31 | 120K | -5.5% |
| FY2023 | 2023-12-31 | 127K | +4.1% |
| FY2022 | 2022-12-31 | 122K | +0.8% |
| FY2021 | 2021-12-31 | 121K | — |
Cost of Revenue vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of -6.4% compares with a peer median of +81.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.36M USD | +63.0% | +84.1% | 43.0% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥131.73M CNY | +352.9% | +81.6% | 23.6% |
| LTM Mar 2026 | $109.99M USD | +25.2% | +56.7% | 16.4% | |
| LTM Sep 2026 | $31.49M USD | +204.6% | +32.7% | 4.8% | |
| LTM Sep 2026 | $12.47M USD | -85.7% | +576.6% | 202.2% | |
| LTM Sep 2026 | $611K USD | -99.2% | — | — | |
| LTM Jun 2026 | $521K USD | — | — | — | |
| LTM Jun 2026 | $408K USD | — | — | — | |
| LTM Mar 2026 | $238.6K USD | — | — | — | |
| LTM Dec 2024 | $120K USD | — | -6.4% | — | |
| LTM Jun 2026 | $47K USD | +33.3% | — | — | |
| Peer median (excluding MENS) | — | +33.3% | +81.6% | 23.6% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 121K | 122K | 127K | 120K | 100K |
| Gross Profit | (121K) | (122K) | (127K) | (120K) | (100K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.56M | 1.29M | 1.07M | 927K | 731K |
| Selling, General & Admin | 845K | 1.54M | 1.73M | 1.13M | 1.78M |
| Operating Expenses | 2.4M | 2.83M | 2.8M | 2.06M | 2.51M |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| EBITDA | (3.24M) | (5.74M) | (3.52M) | (1.86M) | (2.51M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (2.4M) | (2.83M) | (2.8M) | (2.06M) | (2.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 6K | 5K | 56K | 7K | 610K |
| Interest Expense | 835K | 765K | 757K | 1.04M | 2.54M |
| Other Income / Expenses | (1.79M) | (3.8M) | (1.6M) | (963K) | (2.06M) |
| Income Before Tax | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| EPS (Diluted) | (0.06) | (0.09) | (0.06) | (0.04) | (0.06) |
| Weighted Avg Shares | 76.03M | 76.03M | 76.03M | 76.03M | 73.01M |
| Weighted Avg Shares (Diluted) | 76.03M | 76.03M | 76.03M | 76.03M | 73.01M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.